7-HYDRO, OXONOL, & PSEUDO BAN
We Saw This Coming.
We're Just Getting Started.
The DEA just moved to reschedule concentrated 7-OH, Oxonol, and Pseudo. We've spent real time and real R&D preparing for exactly this moment – so while the headlines sound big, our plan hasn't changed. Here's everything you need to know.
What's Actually Happening...
On July 1, 2026, the DEA filed notice to temporarily place concentrated, synthetic 7-hydroxymitragynine (7-OH) – plus a few related lab-made compounds called mitragynine pseudoindoxyl, MGM-15, and MGM-16 – into Schedule I, the most restrictive drug category there is.
In plain English: the government is drawing a hard line between natural kratom and the highly concentrated, synthetic versions of one of its alkaloids that have been showing up in gas stations and smoke shops nationwide. Health regulators say these concentrated products can behave more like traditional opioids than a botanical, and that's the specific thing being targeted.
Here's the part that matters most to you: this doesn't touch kratom itself. It targets a narrow slice of synthetic, ultra-concentrated 7-OH products – which is exactly why our 7-Hydro Tablets, 7-Hydro Shot, Oxonol Tablets, and Pseudo Tablets are affected, while Acend, our Kratom Capsules, and our Kratom & Kava Shots are not.
What to Expect
Here's the thing — we've known a shift like this was coming for a while. That's why Real Botanicals owns its own labs and manufacturing instead of outsourcing to whoever's cheapest. We control our formulas, our testing, and our timeline, which means we don't have to scramble when the rules change.
Our team has put real time and real R&D into anticipating exactly this kind of regulatory shift — reformulating, retesting, and rebuilding our lineup so we're ready to move the moment the rules do. This isn't a fire drill. It's a plan we've been executing for months.
Our ChromaPure purification process — the same one behind every product we make — isn't going anywhere either. So when we say Real Botanicals is just getting started, we mean it. This is a turning point, not a setback.
FAQ's
No. This action targets concentrated, synthetic 7-OH and a few related lab-made compounds — not kratom itself. Regular kratom products, like our Acend Tablets, Kratom Capsules, and Kratom & Kava Shots, aren't part of this.
The DEA's order is expected to take effect as early as August 2026. We'll keep this page updated the moment we know more, and we'll pull affected products from our shelves the day the rule takes effect.
If your subscription includes an affected product, we'll reach out directly with easy options to switch to Acend, Kratom Capsules, or Kratom & Kava Shots — no interruption, no hassle.
Yes — and we're excited about it. We've been developing new formulations behind the scenes for months. More details soon.